About Cerevel Therapeutics

Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy,

Company Highlights
Year Founded

2018

icon-altEmployees

229

Location (HQ)

USA

Since Last Funding

11 months

Monthly Website Visitors

16.6K

icon-altTotal Investment Amt

$1.9B

Last Funding Round

Post Ipo Equity

icon-altMoM Headcount Growth

-5.98%

icon-altYoY Headcount Growth

6.13%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Pharmaceutical

Pharmaceutical Manufacturing

Therapeutics

Biotechnology